Atlas FDA

TDX/TDXFLX CYCLOSPORINE AND METABOLITES WHOLE BLOOD/MONOCLONAL WHOLE BLOOD

FDA premarket approval P890025/S012 · decided 1999-09-29

Approval details

PMA number
P890025
Supplement
S012
Supplement type
Real-Time Process
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
TDX/TDXFLX CYCLOSPORINE AND METABOLITES WHOLE BLOOD/MONOCLONAL WHOLE BLOOD
Generic name
Fluorescence polarization immunoassay for cyclosporine
Applicant
Abbott Laboratories
Date received
1999-09-23
Decision date
1999-09-29
Days to decision
6 days
Decision code
APPR
Product code
MGU
Advisory committee
Clinical Toxicology
Expedited review
No
Location
Abbott Park, IL
Statement
Approval for adding "Caution: This product contains natural dry rubber" to the labeling.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Anti-HCV Next (K252424)Abbott Laboratories2026-04-28
ARCHITECT iGentamicin (K243500)Abbott Laboratories2025-07-09
Alinity i Rubella IgG (K243168)Abbott Laboratories2025-06-20
Alinity h-series System (K243283)Abbott Laboratories2025-02-20
Alinity i Toxo IgM (K233932)Abbott Laboratories2024-08-30
TBI (K232669)Abbott Laboratories2023-09-29
HAVAb IgG II (K222850)Abbott Laboratories2023-08-10
Alinity h-series System (K220031)Abbott Laboratories2023-08-04